The Latest Cardiac and Vascular News
Partnership to Deliver Next-Generation AI Solutions for Radiologists KNOXVILLE, Tenn. and MOUNTAIN VIEW, Calif., Oct. 8, 2024 /PRNewswire/ — RADPAIR, a leader in generative AI-driven radiology reporting solutions, is excited to announce the launch of RADPAIR 2.0, the next iteration of…
DURHAM, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its late-breaking abstract on the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for patients with end-stage renal disease was accepted for an oral presentation at the American Society of Nephrology’s (ASN) Kidney Week 2024. The late-breaking abstract titled “Prospective Randomized Trial of Humacyte’s Acellular Tissue Engineered Vessel Versus Autologous Arteriovenous Fistula for Hemodialysis Access” will be presented at the ASN meeting in San Diego on October 26, 2024.
BERKELEY HEIGHTS, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-five mid-sized dialysis operator for the supply of DefenCath® (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 200 outpatient dialysis clinics located across the United States.
Program reduced all-cause 30-day readmissions for CHF patients by 50 percent using a combination of AI-powered technology and remote human care teams. SOUTHBRIDGE, Mass., Oct. 8, 2024 /PRNewswire/ — UMass Memorial Health – Harrington (“Harrington”), the health and wellness provider for…
HOUSTON, Oct. 8, 2024 /PRNewswire/ — Octagos Health, the leader in AI-powered remote cardiac monitoring, today announced significant advancements in product integration, enhanced AI functionality, and strategic talent investments. Following its recent $43 million Series B funding, the…
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
Amwell today announced Hello Heart is a partner in the Amwell clinical programs portfolio available on the Amwell Converge™ platform.
MINNEAPOLIS, Oct. 8, 2024 /PRNewswire/ — 4C Medical Technologies, Inc. (“4C Medical”), a medical device company dedicated to advancing minimally invasive therapies for structural heart disease, has commenced enrollment in the ATLAS (A Transseptal Left Atrial System for Treatment of…
IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
October 07, 2024 08:00 AM Eastern Daylight Time REDWOOD CITY, Calif.–(BUSINESS WIRE)–InterVene, Inc., a clinical-stage medical device company dedicated to developing interventional solutions for chronic venous insufficiency (CVI), announced today the closing of its $13M Series A financing round. The financing was co-led by new investor Treo Ventures and existing […]
